Efficacy of Platelet-Rich Plasma (PRP) in Ovarian Rejuvenation: A Novel Approach to Address Premature Ovarian Failure and Infertility

Abstract

Premature ovarian failure (POF) is a significant reproductive health challenge, affecting approximately 1% of women under the age of 40. This condition is characterized by diminished ovarian function, hormonal imbalances, and infertility, with limited treatment options offering sustainable results. Platelet-Rich Plasma (PRP) has emerged as a novel therapeutic approach, leveraging growth factors to stimulate ovarian tissue repair and rejuvenation. This study evaluates the efficacy of PRP in women with POF, focusing on its impact on hormonal profiles, follicular development, and clinical outcomes.

A prospective, observational design was employed, involving 30 women diagnosed with POF. Participants received autologous PRP injections into ovarian tissue, and their hormonal levels, antral follicle count (AFC), ovulation rates, and pregnancy outcomes were monitored over six months. Results demonstrated significant reductions in follicle-stimulating hormone (FSH) levels (mean reduction: 30%; p < 0.01) and increases in anti-Müllerian hormone (AMH) levels (mean increase: 20%; p < 0.05). Follicular development improved in 60% of participants, with spontaneous ovulation occurring in 40% and a pregnancy rate of 15%.

These findings underscore PRP's potential as a minimally invasive option for ovarian rejuvenation, offering hope to women with POF. However, variability in response rates emphasizes the need for larger, randomized trials to optimize treatment protocols and establish long-term safety and efficacy. This study contributes to the growing evidence supporting PRP's application in reproductive medicine, paving the way for innovative solutions in infertility management.